Psoriasis Clinical Trial
Daily Topical Rapamycin for Vitiligo
In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% topical rapamycin or 0.001% topical rapamycin for six months to a lesion on one side of the body, and topical placebo to a corresponding lesion on the opposite side of the body. The study also aims to evaluate patient satisfaction and identify any adverse effects on these dosing regimens.
Patients 13 years of age and older
Patients with nonsegmental vitiligo
Patients with segmental or mucosal vitiligo
Patients with contraindication to use of rapamycin
Patients with history of transplant
Patients with a history of natural immunodeficiency
Patients with a history of artificially induced immunodeficiency
Patients with a history of a serious or life-threatening infection
Patients taking CYP3A4 inhibiting medications
Patients taking strong CYP3A4 inducers
Patients undergoing current treatment for vitiligo
Women that are or may become pregnant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Charleston South Carolina, 29425, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.